Primary Biliary Cholangitis (PBC) Clinical Trial
Official title:
Performance of Biochemical Response Criteria and Risk Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
Several risk assessment scoring systems have been proposed to assess the therapeutic response and predict long term prognosis in ursodeoxycholic acid (UDCA)-treated primary biliary cholangitis (PBC) patients, in order to risk stratify PBC patients and guide their management. However there scoring systems have not been fully validated in Chinese population. This study is going to compare the prognostic ability of these criteria, validate the overseas scoring systems, develop and validate a new scoring system in a cohort of Chinese PBC patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03521297 -
Probiotics in PBC Patients of Poor Response to UDCA
|
Phase 2 | |
| Recruiting |
NCT05896124 -
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
|
Phase 2 | |
| Recruiting |
NCT06016842 -
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
|
Phase 3 | |
| Completed |
NCT04047160 -
Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)
|
Phase 1 | |
| Completed |
NCT03124108 -
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
|
Phase 2 |